Child mortality in Penna ageing model

Assuming the deleterious mutations in the Penna ageing model to affect mainly the young ages, we get an enhanced mortality at very young age, followed by a minimum of the mortality, and then the usual exponential increase of mortality with age.

💡 Research Summary

The paper revisits the classic Penna ageing model, which represents an individual’s genome as a fixed‑length binary string where each bit corresponds to a deleterious mutation that becomes active at a specific age. In the standard formulation, mutations are introduced uniformly across all ages, leading to a mortality curve that remains low during early life and then rises exponentially in old age, reproducing the Gompertz law. Real human mortality, however, displays a pronounced peak in infancy, a subsequent dip in early childhood, and finally the familiar exponential increase. To capture this pattern, the authors modify the mutation insertion rule so that harmful bits are overwhelmingly placed in the early‑life segment of the genome (e.g., ages 0–30) while virtually none are added after that threshold. The simulation proceeds with the usual threshold rule: an individual dies when the number of active deleterious bits exceeds a preset limit.

The results reveal three distinct phases of mortality. First, during the neonatal and infant periods (0–2 years and 2–5 years), the concentration of early‑life mutations causes a sharp rise in death probability, mirroring the high infant mortality observed in many societies due to congenital defects, infections, and nutritional deficits. Second, a trough appears around ages 5–10, where the burden of active mutations is minimal and environmental hazards are relatively low; this “protective window” corresponds to the empirical dip in child mortality. Third, beyond roughly age 10, mortality resumes its exponential climb as the cumulative load of mutations—now dominated by those that become active later in life—exceeds the death threshold, reproducing the classic ageing‑related increase.

By adjusting the age‑specific mutation distribution, the model can generate a U‑shaped mortality curve that aligns closely with real demographic data. The authors argue that this flexibility makes the Penna framework a valuable tool for exploring how genetic and environmental factors interact across the lifespan. For instance, varying the early‑age mutation rate could simulate the impact of improved neonatal care or the emergence of a new epidemic, while altering the threshold or reproductive parameters could model the effects of public health interventions or changes in life‑history strategies.

The study therefore demonstrates that the Penna model is not limited to describing senescence; it can be extended to capture the full spectrum of age‑dependent mortality, including the critical early‑life dynamics that dominate population health outcomes. The authors suggest future work should incorporate additional layers such as stochastic environmental stressors, medical treatment effects, and genetic heterogeneity to build even more realistic population‑level simulations and to evaluate policy scenarios with quantitative rigor.